ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer will pay the Paris-based biotech Cellectis $80 million and take a roughly $30 million equity stake in the firm for access to its chimeric antigen receptor T-cell (CAR-T) immunotherapy technology. Pfizer gains exclusive rights to use the CAR-T platform to develop oncology therapies for 15 targets it selects and the right to option therapies based on four targets picked by Cellectis. CAR-T therapy typically involves engineering a patient’s own T cells—a type of white blood cell—to attack cancer cells. Cellectis has found a way to use T cells from a single donor in multiple patients.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter